Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 6/20 | 0.79 |
| ▸ | HTR1A | P08908 | 2/20 | 0.69 |
| ▸ | HTR2C | P28335 | 2/20 | 0.69 |
| ▸ | HTR2B | P41595 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1740704 | 1.00 | TAAR1 (1.00) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL29844954 | 0.98 | TAAR1 (0.96) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| Isobutyraldehyde SCHEMBL11883853 | 0.92 | TAAR1 (0.84) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL29425260 | 0.88 | HTR2A (1.00) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL398581 | 0.88 | HTR2A (1.00) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL398580 | 0.88 | HTR2A (1.00) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL5308097 | 0.86 | HTR2A (0.81) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL5308098 | 0.86 | HTR2A (0.81) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL30341559 | 0.86 | HTR2A (0.96) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL5480637 | 0.85 | TAAR1 (0.73) | TAAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499109-A1 | PSYCHEDELIC COMPOSITIONS AND METHODS FOR FORMING THE SAME | Ojai Energetics PBC (US) | 2025-02-05 | — | — | EP | claimed |
| US-20240390301-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-11-28 | — | — | US | claimed |
| WO-2024191924-A2 | COMPOSITIONS AND METHODS OF USE THEREOF | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2024-09-19 | — | — | WO | claimed |
| US-20240285613-A1 | TREATMENT FOR AUTOIMMUNE DISEASES | LDN Pharma Limited (GB) | 2024-08-29 | — | — | US | claimed |
| US-20240216339-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | US | claimed |
| WO-2024102458-A1 | METHODS OF USING TRAZODONE TO REVERSE THE EFFECTS OF 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| WO-2023183618-A1 | PSYCHEDELIC COMPOSITIONS AND METHODS FOR FORMING THE SAME | OJAI ENERGETICS PBC (US) | 2023-09-28 | — | — | WO | claimed |
| WO-2023028086-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2022261263-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| EP-4720030-A1 | ASYMMETRIC PHENYLALKYLAMINES | Alexander Shulgin Research Institute, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260060979-A1 | METHOD FOR IMPROVING NEUROPLASTICITY | ALTO NEUROSCIENCE INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12534428-B2 | Non-distillative process for manufacturing high purity amphetamines | Pharmapotheca A, Inc. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4673127-A1 | DEUTERATED AND FLUORINATED EMPATHOGENS | Alexander Shulgin Research Institute, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4673430-A2 | PHENYLALKYLAMINE PRODRUGS | Alexander Shulgin Research Institute, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20080075772-A1 | PHARMACEUTICAL COMPOSITIONS HAVING NOVEL SCORING PATTERNS AND METHODS OF USING THOSE COMPOSITIONS | ACCU-BREAK TECHNOLOGIES, INC. | 2008-03-27 | — | — | US | disclosed |
| EP-1868593-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | Hythiam, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
| WO-2006110642-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | HYTHIAM, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-6472227-B1 | A FLUORESCEIN MOIETY IS INCLUDED IN THE TRACER, WHILE A POLY(AMINO ACID) FORMS A PART OF THE IMMUNOGEN FOR DETERMINING THE AMOUNT OF BARBITURATE IN FLUIDS, ESPECIALLY BIOLOGICAL FLUIDS SUCH AS SERUM, PLASMA OR URINE | ABBOTT LABORATORIES | 2002-10-29 | — | — | US | disclosed |
| US-4000197-A | FROM PHENYLACETONES AND METHYL BENZYLAMINE, REDUCTION, HYDROGENOLYSIS | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390301-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR5A | TAAR1 77/4885HTR2A 1/4885HTR1A 4/4885 |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | TAAR1 1075/4885HTR2A 18/4885HTR1A 29/4885 |
| US-12534428-B2 | Non-distillative process for manufacturing high purity amphetamines | SMS, SRMS, SRM | TAAR1 28/4885HTR2A 118/4885HTR1A 84/4885 |
| US-20260060979-A1 | METHOD FOR IMPROVING NEUROPLASTICITY | NTRK2, BDNF, GRIN2A | TAAR1 128/4885HTR2A 13/4885HTR1A 38/4885 |
| US-20240216339-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | HCRTR2, HCRTR1, HTR2A | TAAR1 73/4885HTR2A 3/4885HTR1A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.